3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Withdrawn
1
Completed
1
Sponsor Class
OTHER
2
NIH
1
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Prostatic Neoplasms
26
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasm Metastasis
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large-Cell, Immunoblastic
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Lymphoma
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Burkitt Lymphoma
2
Breast Neoplasms
2
Thromboembolism
1
Sarcoma
1
Prostate Adenocarcinoma
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Kidney Neoplasms
1
Hodgkin Disease
1
Fibrosarcoma
1
Carcinoma, Renal Cell
1
Interventions
Cyclophosphamide
361
Trastuzumab
352
Paclitaxel
304
Docetaxel
272
Capecitabine
222
Letrozole
221
Carboplatin
185
Doxorubicin
181
Tamoxifen
157
Radiotherapy
154
Epirubicin
145
Fulvestrant
143
Anastrozole
139
Surveys and Questionnaires
133
Exercise
128
pertuzumab
113
Vinorelbine
110
Blood Specimen Collection
109
exemestane
106
palbociclib
104
Bevacizumab
104
pembrolizumab
98
Magnetic Resonance Spectroscopy
97
Albumin-Bound Paclitaxel
87
Gemcitabine
84
Drug Therapy
83
Lapatinib
78
130-nm albumin-bound paclitaxel
72
Neoadjuvant Therapy
71
Cisplatin
69
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Breast Neoplasms
×
Estramustine
×
Clear all
NCT02866955
2020-03-09
EFESE
Institut de Cancérologie de Lorraine
Phase 2
Completed
100 enrolled
NCT02853071
2019-11-18
BEST
Centre Hospitalier Universitaire de Besancon
Phase 2
Withdrawn